|
|
Start year |
End year |
Title |
Source |
Position |
| 1. |
|
2009 |
|
Predictive markers of a combination cetuximab and sorafenib response and toxicity |
Bayer Correlative Study Fund |
Principal Investigator |
| 2. |
|
2008 |
2009 |
The role of Human Papilloma Virus in deregulation of microRNAs in head and neck squamous cell carcinoma |
Radiation Therapy Oncology Group Seed Grant |
Principal Investigator |
| 3. |
|
2008 |
2009 |
Insulin-like growth factor I receptor as a therapeutic target in non-small cell lung cancer |
Vanderbilt Lung SPORE Pilot Grant |
Principal Investigator |
| 4. |
|
2007 |
2009 |
Predictive markers of efficacy and toxicity in head and neck patients treated with Oxaliplatin and Pemetrexed |
Lilly Oncology Research Fund |
Principal Investigator |
| 5. |
|
2007 |
|
Molecular signatures on HNSCC in response to targeted therapies |
National Institutes of Health |
Principal Investigator |
| 6. |
|
2004 |
2007 |
Molecular Determinants of Cell Invasion |
Vanderbilt/Astra-Zeneca Alliance Research Fund |
Principal Investigator |
| 7. |
|
2005 |
|
Gene expression-based outcome prediction in head and neck cancer |
Damon-Runyon Clinical Investigator |
Principal Investigator |
| 8. |
|
2003 |
2005 |
Head and neck tumor classification based on gene expression profiles and its clinical implication. |
Vanderbilt Physician-Scientist |
Principal Investigator |
| 9. |
|
2003 |
2005 |
Gene expression as predictor of metastasis in HNSCC |
R21: National Cancer Institute |
Principal Investigator |
How We Rank
